Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrativ... (n a cohortof women who have been heavily...)

HOME >> MEDICINE >> TECHNOLOGY

Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology

Date:11/20/2008

n a cohort of women who have been heavily, but unsuccessfully, pretreated for metastatic breast cancer," said Dr. Mary Tagliaferri, President and Chief Medical Officer of Bionovo.

Overall compliance with study medication was excellent with 90% of prescribed doses taken. The most common side effects experienced by women in the Phase 1B clinical trial were mild diarrhea and nausea.

"We are encouraged by the results of the Company's second Phase 1 trial in women with advanced breast cancer," said Isaac Cohen, Chairman and CEO of Bionovo. "There are currently over 160,000 women in the United States living with advanced breast cancer who are eagerly awaiting an oral anticancer drug with minimal side effects and the ability to extend life without profoundly diminishing their quality of life. We believe BZL101 may be an important new anticancer agent because its biological selectivity allows the drug to kill cancer cells without affecting normal cells. This will lead to a dramatically lower side effect profile."

Phase 2 Clinical Trial

The Phase 2 clinical trial is currently enrolling 80 women diagnosed with advanced, measurable breast cancer who have received no more than two prior cytotoxic cancer therapies.

The trial is open at the following clinical sites under the directorship of the listed investigators:

Institution Site Principle Investigator
California Cancer Care Inc.,
Greenbrae/San Mateo, California Dr. Peter Eisenberg
Columbia Presbyterian Medical Center,
New York, New York Dr. Dawn Hershman
Comprehensive Cancer Center at Desert Regional
Medical Center, Palm Springs, California Dr. Gail Leichman
Duke University, Durham, North Carolina Dr. Gretchen Kimmick
Lynn Regional Cancer Center, Boca Raton, Florid
'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved
0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
2. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
3. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
4. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
7. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
8. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
9. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
10. Lytix Presents LTX-109 Anti-Microbial Data at ICAAC
11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium

Post Your Comments:

Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrativ...(n a cohortof women who have been heavily...),Health